Ondansetron Aspire (Ondansetron)

Ondansetron Aspire is a selective 5‑HT3 receptor antagonist used in the prevention and treatment of nausea and vomiting associated with several clinical pathways.

• Chemotherapy‑induced nausea and vomiting (CINV): Reduces the frequency and severity of acute and delayed episodes.
• Radiation‑induced nausea and vomiting (RINV): Decreases the incidence of nausea during and after radiotherapy.
• Post‑operative nausea and vomiting (PONV): Lowers the risk of nausea and vomiting following surgical procedures.
• Hyperemesis gravidarum (severe pregnancy‑related nausea): Provides symptomatic relief when other treatments are insufficient.

• Ondansetron blocks serotonin (5‑HT3) receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By inhibiting this receptor, it prevents the initiation of the vomiting reflex triggered by chemotherapeutic agents, radiation, or surgical stimuli, thereby reducing nausea and vomiting.

Side effects of ondansetron are generally mild but can vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate intensity.
• Constipation: reduced bowel movements or hard stools.
• Diarrhoea: loose stools, usually transient.
• Fatigue: feeling of tiredness or lack of energy.
• Dizziness: light‑headed sensation, often short‑lived.

Serious or Rare Side Effects

• Cardiac arrhythmia: QT‑interval prolongation that may lead to irregular heart rhythm.
• Severe allergic reaction: rash, itching, swelling, or difficulty breathing.
• Serotonin syndrome: agitation, hyperreflexia, tremor, or fever when combined with other serotonergic drugs.
• Hepatic dysfunction: elevated liver enzymes indicating liver stress.
• Vision changes: blurred vision or visual disturbances.

When using Ondansetron Aspire, consider the following safety measures:

• Cardiac assessment: Evaluate baseline ECG in patients with known cardiac disease or electrolyte imbalance.
• Electrolyte monitoring: Correct hypokalaemia, hypomagnesemia, or hypocalcaemia before initiation.
• Drug interactions: Review concomitant medications for serotonergic activity or QT‑prolonging potential.
• Pregnancy and lactation: Use only if the potential benefit outweighs the risk; discuss with a healthcare professional.
• Renal/hepatic impairment: Dose adjustment may be required; monitor liver and kidney function.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ondansetron may interact with several drug classes, requiring attention to the interaction severity.

Major Interactions (Avoid)

• Other QT‑prolonging agents (e.g., quinidine, sotalol, certain anti‑arrhythmics): increased risk of serious cardiac arrhythmias.
• Serotonergic drugs (e.g., SSRIs, MAO inhibitors, tramadol): heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase ondansetron plasma levels.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce ondoxetine efficacy.
• Anticholinergic agents: may diminish anti‑emetic effect.
• Digoxin: potential increase in serum digoxin concentrations.
• Oral contraceptives: possible reduction in hormonal efficacy.